Blujepa is one of 3 small molecule programs targeting Urinary Tract Infections. It is currently in Phase 1.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
2 competitors in Urinary Tract Infections
Bactrim
Blujepa
Methenamine Hippurate 1g BD
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Mar 25, 2025
BLUJEPA
NDA NDA218230
Sources
Details